A Phase 2b, Multicenter, Long-term Extension Study of Setrusumab in Adults With Type I, III, or IV Osteogenesis Imperfecta
Latest Information Update: 25 Oct 2022
At a glance
- Drugs Setrusumab (Primary)
- Indications Osteogenesis imperfecta
- Focus Registrational; Therapeutic Use
- Sponsors Ultragenyx Pharmaceutical
- 19 Oct 2022 Status changed from active, no longer recruiting to discontinued.
- 19 Sep 2022 Status changed from recruiting to active, no longer recruiting.
- 02 May 2022 Status changed from not yet recruiting to recruiting.